Biobanking - Evaluating the Benefits of Public-Private Partnerships
In this interview Heli Salimen-Mankonen, Research Director, Auria Biobank, speaks to Andrea Charles from Pharma IQ about forming and sustaining public-private partnerships and the evaluating the benefits of this collaboration.
Pharma IQ: What are the key differences between the sectors?
H Salimen-Mankonen: Human biological samples and medical data are provided as donations and are considered as common goods, while the private industry sector needs access to biospecimen and data to de...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.